After this year’s Nobel Prize, the first results for a CAR-Treg for autoimmune disease are innews2025-10-29T15:31:04+00:00October 29th, 2025|Endpoints News|
What Novo Nordisk might be planning to turn the ship aroundnews2025-10-29T15:23:20+00:00October 29th, 2025|Endpoints News|
Novo Nordisk’s direct-to-patient platform gains momentum as self-pay sales risenews2025-10-29T15:23:01+00:00October 29th, 2025|Endpoints News|
Kyverna says small group of rare disease patients all responded to its CAR-Tnews2025-10-29T14:44:27+00:00October 29th, 2025|Endpoints News|
Recursion gets $30M from Roche; Chinese siRNA biotech to go public in Hong Kong news2025-10-29T14:32:31+00:00October 29th, 2025|Endpoints News|
Regeneron teams up with Gary Nabel’s ModeX on multispecificsnews2025-10-29T14:22:25+00:00October 29th, 2025|Endpoints News|
Scribing startups are reinventing themselves beyond notetaking as shakeout nearsnews2025-10-29T13:00:07+00:00October 29th, 2025|Endpoints News|
Weight loss drugs could be cost-effective even at higher prices, ICER saysnews2025-10-29T12:21:07+00:00October 29th, 2025|Endpoints News|
GSK trims pipeline, bumps guidance in Emma Walmsley’s last earnings reportnews2025-10-29T11:34:00+00:00October 29th, 2025|Endpoints News|
BridgeBio gets another Phase 3 rare disease win, this time in thyroid disordernews2025-10-29T11:00:39+00:00October 29th, 2025|Endpoints News|
